Oppenheimer Raises Blackstone Target to $168 and Amgen Target to $480
Oppenheimer lifted its Blackstone price target to $168 from $164 and kept its Outperform rating. Its Amgen target rose to $480 from $450.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Oppenheimer analysts raised their price target on Blackstone to $168 per share from $164. The firm kept its Outperform rating on the asset manager.
For Amgen, Oppenheimer increased its target to $480 from $450 per share. The rating changes were reported by Dow Jones Newswires, citing Benzinga.
why it matters
Price target revisions like these are routine and usually affect only the individual stocks involved. They reflect a higher analyst valuation for each company rather than a forecast of where the shares will trade.
market impact
Stocks BX and AMGN: higher target prices reflect more positive analyst views on both companies
tags
instruments
sources
- Blackstone Price Target Raised to $168.00/Share From $164.00 by Oppenheimer — Dow Jones Newswires, 23 October 2026 at 17:15 UTC
- Amgen Price Target Raised to $480.00/Share From $450.00 by Oppenheimer — Dow Jones Newswires, 23 October 2026 at 17:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗